Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2022 Earnings Call Transcript

It’s always a challenge to make sure you line around value and align around timing of how value gets created. And my view of the world is we understand the value of our asset, and we won’t do anything less than achieving that value. So I think we’re in a good position both with sota in terms of where we are at the FDA, and we’re in a good position to keep advancing sotagliflozin forward. That’s what the FDA meeting is about. And I think once we conclude that, we should be in a position to advance it into Phase 3. And my hope is, if we get alignment we’ll be able to do that in some type of broad framework partnership. I think those were the three.

Jeff Wade: Al1 right, any other questions?

Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Lonnel Coats for any closing remarks.

Lonnel Coats: Well, thank you, everyone, for joining us on today’s call and for your continued support of Lexicon. I would like to close out by summarizing a couple of key milestones and events. First of LX9211 based on the completion of, as we’ve said, two proof-of-concept studies in diabetic peripheral neuropathic pain and postherpetic neuralgia, planning and preparations for a Phase 3 development program are underway and we will be able to share more about these plans as the year progresses. Second, we have successfully completed a life cycle review meeting with FDA for our new drug application for sotagliflozin heart failure and remain on track for our PDUFA date of May 27. And we plan to launch sotagliflozin in heart failure in the first half of 2023.

Finally, importantly, Lexicon is in a strong position €“ cash position with the ability to fund operations well past the initial launch of sotagliflozin and heart failure, if approved. This has been a tremendous quarter for the company and for our stakeholders, and we expect these milestones to only increase value for all of our stakeholders in 2023. Look forward to continuing to communicate events out to you as they occur. Thank you very much for joining us.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.